Integra Lifesciences Holdings Corp [IART] stock is trading at $26.05, up 1.76%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The IART shares have gain 12.09% over the last week, with a monthly amount glided 19.50%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Integra Lifesciences Holdings Corp [NASDAQ: IART] stock has seen the most recent analyst activity on December 02, 2024, when Morgan Stanley initiated its Underweight rating and assigned the stock a price target of $20. Previously, BTIG Research upgraded its rating to Neutral on October 07, 2024. On July 30, 2024, downgrade downgraded it’s rating to Sell and revised its price target to $23 on the stock. BTIG Research downgraded its rating to a Sell but stick to its price target of $22 on July 30, 2024. Wells Fargo downgraded its rating to a Equal Weight and reduced its price target to $25 on May 07, 2024. Oppenheimer downgraded its rating to Perform for this stock on May 07, 2024. In a note dated April 03, 2024, Citigroup upgraded an Neutral rating on this stock but restated the target price of $38.
Integra Lifesciences Holdings Corp [IART] stock has fluctuated between $16.81 and $45.42 over the past year. Currently, Wall Street analysts expect the stock to reach $23 within the next 12 months. Integra Lifesciences Holdings Corp [NASDAQ: IART] shares were valued at $26.05 at the most recent close of the market. An investor can expect a potential drop of -11.71% based on the average IART price forecast.
Analyzing the IART fundamentals
Integra Lifesciences Holdings Corp [NASDAQ:IART] reported sales of 1.56B for the trailing twelve months, which represents a drop of -0.41%. Gross Profit Margin for this corporation currently stands at 0.56% with Operating Profit Margin at 0.06%, Pretax Profit Margin comes in at -0.01%, and Net Profit Margin reading is -0.0%. To continue investigating profitability, this company’s Return on Assets is posted at -0.0, Equity is -0.0 and Total Capital is 0.03. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of1.31.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 25.50 points at the first support level, and at 24.94 for the second support level. However, for the 1st resistance point, the stock is sitting at 26.46, and for the 2nd resistance point, it is at 26.86.
Ratios To Look Out For
For context, Integra Lifesciences Holdings Corp’s Current Ratio is 1.20. Further, the Quick Ratio stands at 0.73, while the Cash Ratio is 0.24. Considering the valuation of this stock, the price to sales ratio is 1.28, the price to book ratio is 1.32.
Transactions by insiders
Recent insider trading involved Schwartz Eric, EVP, Chief Legal Officer & Sec, that happened on Dec 03 ’24 when 4070.0 shares were sold. Officer, Schwartz Eric completed a deal on Dec 03 ’24 to buy 4070.0 shares. Meanwhile, EVP & President, CSS McBreen Michael J. sold 1700.0 shares on Dec 02 ’24.
